If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

Share Price is delayed by 15 minutes
Get Live Data
6.10    0.00 (0.00%)
Bid:
6.00
Ask:
6.20
Spread: 0.20 (3.333%)
Market Cap: £65.24m
STX Live PriceLast checked at - London Stock Exchange

Intraday Shield Thera Share Chart

Holding(s) in Company

4 May 2018 09:20

RNS Number : 1547N
Shield Therapeutics PLC
04 May 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Shield Therapeutics plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

JPMorgan Asset Management Holdings Inc.

City and country of registered office (if applicable)

Wilmington, United States of America

4. Full name of shareholder(s) (if different from 3.)v

Name

J.P. Morgan Investment Management Inc.

· JPM Global Healthcare Fund

City and country of registered office (if applicable)

London, United Kingdom

5. Date on which the threshold was crossed or reachedvi:

01 May 2018

6. Date on which issuer notified (DD/MM/YYYY):

03 May 2018

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

Below minimum threshold

Below minimum threshold

Below minimum threshold

116,425,851

Position of previous notification (if

applicable)

5.37%

0.00%

5.37%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BYV81293

Below minimum threshold

Below minimum threshold

SUBTOTAL 8. A

Below minimum threshold

Below minimum threshold

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

JPMorgan Asset Management Holdings Inc.

J.P. Morgan Investment Management Inc.

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

Chain of controlled undertakings:

 

JPMorgan Asset Management Holdings Inc.(100%)

J.P. Morgan Investment Management Inc. (100%)

 

 

Place of completion

London, United Kingdom

Date of completion

03 May 2018

 

Notes

 

i Please note that national forms may vary due to specific national legislation (Article 3(1a) of Directive 2004/109/EC) as for instance the applicable thresholds or information regarding capital holdings.

 

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.

 

iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.

 

iv This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h)/ Article 10 (b) to (h) of Directive 2004/109/EC; (c) all parties to the agreement referred to in Article 10 (a) of Directive 2004/109/EC (DTR5.2.1 (a)) or (d) the holder of financial instruments referred to in Article 13(1) of Directive 2004/109/EC (DTR5.3.1).

 

As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.

 

In relation to the transactions referred to in points (b) to (h) of Article 10 of Directive 2004/109/EC (DTR5.2.1 (b) to (h)), the following list is provided as indication of the persons who should be mentioned:

 

- in the circumstances foreseen in letter (b) of Article 10 of that Directive (DTR5.2.1 (b)), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

 

- in the circumstances foreseen in letter (c) of Article 10 of that Directive (DTR5.2.1 (c)), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

 

- in the circumstances foreseen in letter (d) of Article 10 of that Directive (DTR5.2.1 (d)), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

 

- in the circumstances foreseen in letter (e) of Article 10 of that Directive (DTR5.2.1 (e)), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under Article 9 (DTR 5.1), under letters (a) to (d) of Article 10 of that Directive (DTR5.2.1 (a) to (d)) or under a combination of any of those situations, the controlled undertaking;

 

- in the circumstances foreseen in letter (f) of Article 10 of that Directive (DTR5.2.1 (f)), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

 

- in the circumstances foreseen in letter (g) of Article 10 of that Directive (DTR5.2.1 (g)), the natural person or legal entity that controls the voting rights;

 

- in the circumstances foreseen in letter (h) of Article 10 of that Directive (DTR5.2.1 (h)), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).

 

v Applicable in the cases provided for in Article 10 (b) to (h) of Directive 2004/109/EC (DTR5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in Article 10 of that Directive (DTR5.2) unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with national practices (e.g. identification of funds managed by management companies).

 

vi The date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect.

 

vii The total number of voting rights shall be composed of all the shares, including depository receipts representing shares, to which voting rights are attached even if the exercise thereof is suspended.

 

viii If the holding has fallen below the lowest applicable threshold in accordance with national law, please note that it might not be necessary in accordance with national law to disclose the extent of the holding, only that the new holding is below that threshold.

 

ix In case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

 

x Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

 

xi If the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].

 

xii In case of cash settled instruments the number and percentages of voting rights is to be presented on a delta-adjusted basis (Article 13(1a) of Directive 2004/109/EC) (DTR 5.3.3.A).

 

xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

 

xiv The full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity has to be presented also in the cases, in which only on subsidiary level a threshold is crossed or reached and the subsidiary undertaking discloses the notification as only thus the markets get always the full picture of the group holdings. In case of multiple chains through which the voting rights and/or financial instruments are effectively held the chains have to be presented chain by chain leaving a row free between different chains (e.g.: A, B, C, free row, A, B, D, free row, A, E, F etc.).

 

xv The names of controlled undertakings through which the voting rights and/or financial instruments are effectively held have to be presented irrespectively whether the controlled undertakings cross or reach the lowest applicable threshold themselves.

 

xvi Example: Correction of a previous notification.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLAIMPTMBBMMRP
Date   Source Headline
30th Jun 20267:52 amRNSBlock Listing 6 Monthly Return
18th Jun 20264:20 pmRNSResults of 2026 Annual General Meeting
29th May 20269:11 amRNSTotal Voting Rights
5th May 20267:00 amRNSGrant of Share Options
1st May 20267:00 amRNSQ1 2026 Trading Update
30th Apr 20267:01 amRNSTotal Voting Rights
27th Apr 20267:00 amRNSEnrollment in Phase II Clinical Trial for ACCRUFeR
9th Apr 202612:30 pmRNSAudited results for year ended 31 December 2025
1st Apr 20269:22 amRNS-RPublication of Report, Reinforcing FDA Approval
31st Mar 20267:03 amRNSTotal Voting Rights
31st Mar 20267:00 amRNSEMA approves extension - to include adolescents
3rd Mar 20267:00 amRNSChinese NMPA Accepts MAA Submission for ACCRUFeR®
27th Feb 20267:00 amRNSTotal Voting Rights
9th Feb 20267:00 amRNSFDA Grants additional Exclusivity for ACCRUFeR
30th Jan 20267:05 amRNSTotal Voting Rights
30th Jan 20267:00 amRNSApproval for ACCRUFeR in China expected in Q1 2026
21st Jan 20267:00 amRNSQ4 2025 Trading Update
2nd Jan 202611:06 amRNSBlock listing 6 Monthly Return
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
22nd Dec 20257:00 amRNSFDA approves extension for ACCRUFeR®
22nd Dec 20257:00 amRNSFDA approves extension for ACCRUFeR®
18th Dec 20257:13 amRNSBlock Listing Application
11th Dec 20257:00 amRNS-RShield Wins Gold at Titan Branding Awards
3rd Dec 20257:04 amRNSAmends Senior Secured Debt Financing
14th Nov 20257:03 amRNSInitiation of a Phase II Clinical Trial in Japan
11th Nov 20257:00 amRNSACCRUFeR Pediatric PK Results to be Presented
7th Nov 20257:03 amRNSACCRUFeR receives Authorisation by Korean Ministry
23rd Oct 20257:00 amRNSQ3 2025 Trading Update
14th Oct 20253:01 pmRNSGrant of Share Options to Chief Executive Officer
1st Oct 20258:00 amRNSTotal Voting Rights
1st Oct 20257:02 amRNSPositive efficacy and tolerance in pediatric trial
15th Sep 20257:00 amRNS£1.5 million placing supporting growth of ACCRUFeR
4th Sep 20257:03 amRNSACCRUFeR® assigned Priority Review in US by FDA
3rd Sep 20252:17 pmRNSInterim results for the six months ended 30 Jun 25
27th Aug 20257:13 amRNSData published -European Journal of Heart Failure
21st Aug 202512:06 pmRNSInterim results for the six months ended 30 Jun 25
23rd Jul 20257:00 amRNSQ2 2025 Trading Update
22nd May 20255:06 pmRNSResult of AGM
24th Apr 20257:06 amRNSAudited results for the year ended 31 Dec 2024
22nd Apr 20257:01 amRNSLicence Agreement in Japan for ACCRUFeR®
17th Apr 202511:23 amRNSQ1 2025 Trading Update
11th Mar 20257:00 amRNSACCRUFeR® launched in Canada
13th Feb 20254:15 pmRNSPDMR Transaction Notification
13th Feb 20257:00 amRNSGrant of Share Options
5th Feb 20257:00 amRNSUnaudited full year trading update
27th Jan 20257:00 amRNSAnders Lundstrom appointed CEO
24th Dec 202411:25 amRNSResult of General Meeting & Total Voting Rights
23rd Dec 20247:00 amRNSResults of RetailBook Offer
6th Dec 202411:31 amRNSRetailBook Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.